. 2015 Oct;7().
doi: 10.2147/BCTT.S91981.

Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes

Yehoda M Martei 1 Jennifer M Matro 2 
  • PMID: 26504408
  •     50 References
  •     3 citations


Identifying patients at high risk of breast cancer recurrence has important implications not only for enabling the ability to provide accurate information to patients but also the potential to improve patient outcomes. Patients at high recurrence risk can be offered appropriate treatment to improve the overall survival. However, the major challenge is identifying patients with early-stage breast cancer at lower risk who may be spared potentially toxic therapy. The successful integration of molecular assays into clinical practice may address the problem of overtreatment and improve overall patient outcomes.

Keywords: breast cancer; early stage; genomic assays; recurrence risk; recurrence score.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
Howard Y Chang, Dimitry S A Nuyten, +10 authors, Marc J van de Vijver.
Proc Natl Acad Sci U S A, 2005 Feb 11; 102(10). PMID: 15701700    Free PMC article.
Highly Cited.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
John M S Bartlett, Kenneth J Bloom, +13 authors, Daniel Rea.
J Clin Oncol, 2012 Oct 10; 30(36). PMID: 23045591
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 Apr 12; 24(13). PMID: 16606972
Highly Cited.
Breast cancer prognostic factors: evaluation guidelines.
W L McGuire.
J Natl Cancer Inst, 1991 Feb 06; 83(3). PMID: 1988696
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G Bonadonna, P Valagussa, +2 authors, C Brambilla.
N Engl J Med, 1995 Apr 06; 332(14). PMID: 7877646
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.
B Fisher, C Redmond, +7 authors, Y Pilch.
N Engl J Med, 1989 Mar 30; 320(13). PMID: 2927449
Highly Cited.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
HER2 as a prognostic and predictive marker for breast cancer.
T Cooke, J Reeves, A Lanigan, P Stanton.
Ann Oncol, 2001 Aug 28; 12 Suppl 1. PMID: 11521717
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, +13 authors, H D Bear.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704717
Highly Cited.
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
Richard M Simon, Soonmyung Paik, Daniel F Hayes.
J Natl Cancer Inst, 2009 Oct 10; 101(21). PMID: 19815849    Free PMC article.
Highly Cited.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
John M S Bartlett, Jeremy Thomas, +12 authors, Udi Chetty.
Breast Cancer Res, 2010 Jul 10; 12(4). PMID: 20615243    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.
P P Rosen, S Groshen, +2 authors, S Hellman.
J Clin Oncol, 1989 Sep 01; 7(9). PMID: 2549203
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Prognostic molecular markers in early breast cancer.
Francisco J Esteva, Gabriel N Hortobagyi.
Breast Cancer Res, 2004 Apr 16; 6(3). PMID: 15084231    Free PMC article.
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.
Maria Vittoria Dieci, Enrico Orvieto, +2 authors, Valentina Guarneri.
Oncologist, 2014 Jun 28; 19(8). PMID: 24969162    Free PMC article.
A prognostic index in primary breast cancer.
J L Haybittle, R W Blamey, +5 authors, K Griffiths.
Br J Cancer, 1982 Mar 01; 45(3). PMID: 7073932    Free PMC article.
Highly Cited.
The relationship between prognostic and predictive factors in the management of breast cancer.
I C Henderson, A J Patek.
Breast Cancer Res Treat, 1999 Mar 05; 52(1-3). PMID: 10066087
Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators.
E R Fisher, J Costantino, B Fisher, C Redmond.
Cancer, 1993 Mar 15; 71(6 Suppl). PMID: 8443763
S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.
J Bryant, B Fisher, +2 authors, B Emir.
Breast Cancer Res Treat, 1999 Mar 06; 51(3). PMID: 10068082
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Catherine M Kelly, Philip S Bernard, +7 authors, Lajos Pusztai.
Oncologist, 2012 Mar 16; 17(4). PMID: 22418568    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
A Goldhirsch, J H Glick, R D Gelber, H J Senn.
J Natl Cancer Inst, 1998 Nov 12; 90(21). PMID: 9811309
Do we need prognostic factors in nodal-negative breast cancer? Arbiter.
D F Hayes.
Eur J Cancer, 2000 Mar 10; 36(3). PMID: 10708930
The MINDACT trial: the first prospective clinical validation of a genomic tool.
Fatima Cardoso, Martine Piccart-Gebhart, +2 authors, TRANSBIG Consortium.
Mol Oncol, 2007 Dec 01; 1(3). PMID: 19383299    Free PMC article.
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
B Fisher, J Costantino, +7 authors, E R Fisher.
N Engl J Med, 1989 Feb 23; 320(8). PMID: 2644532
Highly Cited.
A suggested classification of breast pain.
H M Bishop, R W Blamey.
Postgrad Med J, 1979 Jan 01; 55 Suppl 5. PMID: 231775
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
C Williams, S Brunskill, +8 authors, M Lodge.
Health Technol Assess, 2006 Sep 09; 10(34). PMID: 16959170
Systematic Review.
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Douglas T Ross, Chung-Yeul Kim, +7 authors, Norman Wolmark.
Clin Cancer Res, 2008 Oct 18; 14(20). PMID: 18927301    Free PMC article.
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
John A Foekens, David Atkins, +17 authors, Yixin Wang.
J Clin Oncol, 2006 Mar 01; 24(11). PMID: 16505412
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Emiel Rutgers, Martine J Piccart-Gebhart, +12 authors, Fatima Cardoso.
Eur J Cancer, 2011 Nov 05; 47(18). PMID: 22051734
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.
A C Voogd, M Nielsen, +8 authors, Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.
J Clin Oncol, 2001 Mar 17; 19(6). PMID: 11250998
Highly Cited.
Tubular carcinoma of the breast: further evidence to support its excellent prognosis.
Emad A Rakha, Andrew H S Lee, +6 authors, Ian O Ellis.
J Clin Oncol, 2009 Nov 18; 28(1). PMID: 19917872
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
A Caldarella, C Buzzoni, +8 authors, E Paci.
J Cancer Res Clin Oncol, 2012 Dec 28; 139(4). PMID: 23269487
Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants.
E R Fisher, S Anderson, C Redmond, B Fisher.
Cancer, 1993 Apr 15; 71(8). PMID: 8453574
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P Eifel, J A Axelson, +11 authors, D Roter.
J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563
Highly Cited. Review.
Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
James E Frampton.
Drugs, 2017 Nov 28; 77(18). PMID: 29177573
Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option?
Elisa M Schunkert, Wanzhou Zhao, Kurt Zänker.
Biomed Hub, 2018 Nov 01; 3(3). PMID: 31988964    Free PMC article.
Effect of an Artificial Intelligence Clinical Decision Support System on Treatment Decisions for Complex Breast Cancer.
Fengrui Xu, Martín-J Sepúlveda, +13 authors, Kyu Rhee.
JCO Clin Cancer Inform, 2020 Sep 25; 4. PMID: 32970484    Free PMC article.